Weight loss injections should be investigated as potential "cancer prevention agents", experts have urged, following a study that linked the medication to a reduced risk of cancers associated with obesity.
Being overweight or obese is a known risk factor for 13 types of cancer, including those affecting the breast, bowel, pancreas, kidney, liver, and stomach. Glucagon-like peptide-1 receptor agonist (GLP-1) drugs, such as Mounjaro, Wegovy, and Ozempic, are currently prescribed to treat obesity and type 2 diabetes. However, new research suggests that the use of these medications could offer wider health benefits beyond their primary indications.
